What happens after an oral ingestion of haloperidol decanoate? – A case report

• Main Authors: João Perestrelo, Ana Coutinho, Georgina Lapa
• Format: Article
• Language: English
• Published: Universidade Federal do Rio de Janeiro 2019-05-01
• Series: Jornal Brasileiro de Psiquiatria
• Subjects: Antipsychotic; ingestion; haloperidol decanoate; treatment; schizophrenia
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0047-20852019000100056&lng=en&tlng=en

ABSTRACT Haloperidol decanoate is a first generation antipsychotic drug used to treat patients with schizophrenic disorder who require prolonged parenteral antipsychotic therapy. Cases of oral haloperidol decanoate are rare, and only one has been reported in foreign literature. In this report, we present a case of an oral ingestion of haloperidol decanoate of a male with schizophrenic disorder who presented to the emergency department following an oral ingestion of 1 ampoule of haloperidol decanoate 100 mg. At presentation he was hemodynamically stable. He was maintained on vigilance for 12 hours after what was discharged to the outpatient unit for psychiatric follow-up. The bioavailability and pharmacokinetic of oral intake of haloperidol decanoate are unknown. Although there is a report of treatment with oral activated charcoal in this case there was no need of intervention.